The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.
The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.
The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.
The investment bank said it is encouraged by the company's strong pipeline and position among its competitors but sees further upside for its stock.
In a recent study in Blood, the researchers showed that a higher allelic burden after transplantation was associated with higher risk of relapse and mortality.
The company also said it launched a new comprehensive diagnostic called HeartCare for surveillance of heart transplant patients.
The researchers were able to diagnose 17 patients with short telomere syndrome based on telomere length combined with targeted sequence data.
The company outlined its plans to launch a kidney transplant rejection test that is based on cell-free DNA in 2019 and described its progress in breast cancer research.
Cornell researchers plan to test cell-free DNA in a prospective study for diagnosing infection and antimicrobial resistance in kidney transplant patients.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.